Figure 4

Cumulative incidence of MACE according to the statin intensity and dose. (A) Cumulative incidence of MACE according to the statin intensity. Patients treated with high-intensity statin showed a significantly lower cumulative incidence of MACE compared to the moderate-intensity statin group (11.6% vs. 14.1%, P = 0.004). (B) Cumulative incidence of MACE according to the atorvastatin dose. A higher dose was associated with a lower cumulative incidence of MACE (80 mg vs. 40 mg vs. 20 mg vs. 10 mg: 8.5% vs. 15.0% vs. 12.0% vs. 8.5%, respectively, P < 0.001). MACE major adverse cardiac events.